TABLE 1.
Patient Demographics and Medication
| Period 1 (N = 139) | Period 2 (N = 95) | P Value | |
| Age (mean (SD) (yrs) | 70 (±11) | 67 (±12) | 0.10† |
| Sex (M:F) | 102:37 | 64:31 | 0.38∗ |
| IHD n (%) | 46 (33) | 31 (32) | 0.52∗ |
| Stoke/TIA n (%) | 18 (13) | 8 (8) | 0.12∗ |
| DM n (%) | 84 (60) | 57 (60) | 0.52∗ |
| Smoker n (%) | 112 (81) | 57 (60) | 0.02∗ |
| Hypertension n (%) | 104 (75) | 82 (86) | 0.034∗ |
| Hypercholesterolaemia n (%) | 72 (52) | 63 (64) | 0.06∗ |
| eGFR (mean (SD) (ml/min/1.73 m2) | 75 (±36) | 74 (±50) | 0.90† |
| Renal replacement therapy | 4 (3) | 8 (8) | 0.072∗ |
| Preoperative anticoagulation | |||
| Warfarin | 8 (6) | 6 (6) | |
| Direct oral anticoagulant (DOAC) | 11 (8) | 16 (17) | 0.09∗ |
| Low molecular weight heparin | 5 (4) | 7 (7) | |
| Preoperative antiplatelets | |||
| Aspirin | 63 (45) | 33 (35) | |
| Clopidogrel | 18 (13) | 12 (13) | 0.001∗ |
| Dual antiplatelets | 8 (6) | 15 (16) | |
| Postoperative anticoagulation | |||
| Warfarin | 9 (6) | 9 (6) | |
| Direct oral anticoagulant (DOAC) | 15 (11) | 18 (19) | 0.001∗ |
| Low molecular weight heparin | 6 (4) | 16 (17) | |
| Postoperative antiplatelets | |||
| Aspirin | 29 (21) | 31 (33) | |
| Clopidogrel | 41 (29) | 19 (20) | 0.001∗ |
| Dual antiplatelets | 59 (42) | 26 (27) | |
∗
Chi-Square.
†
Unpaired t-test.
DM indicates diabetes mellitus; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; TASC, Transatlantic Inter-Society Consensus; TIA, transient ischaemic attack.